AstraZeneca’s £93m headache as it dumps another new drug
Struggling AstraZeneca today faced yet another blow when it had to dump a new arthritis treatment because clinical trials showed patients were hit with side-effects including the common cold.
Pulling development on fostamatinib, a rheumatoid arthritis pill, means a $140 million (£93 million) impairment charge. But analysts were more worried about Astra’s floundering pipeline. The experimental medicine was one of the very few late-stage drugs in Astra’s research labs, and Britain’s second-biggest drugmaker had put it through clinical trials for two and a half years, on more than 2100 patients.
Fostamatinib, which Astra was working on with US biotech Rigel Pharmaceuticals, was seen as a potential competitor to drugs such as Abbott Laboratories’ Humira, the world’s best-selling prescription medicine, in an arthritis market worth $20 billion (£13 billion).
But Astra admitted patients taking part in the drug’s trials had faced a cocktail of side-effects including hypertension, diarrhoea, nausea, headache and colds. Analysts said that meant more than six drug failures from Astra’s pipeline in recent years. A string of AstraZeneca’s big-selling drugs fell out of patent last year, leaving revenues down 17%. The US patents for its best-selling drugs, Nexium ulcer pills and cholesterol-buster Crestor, expire within three years.
Threat of 'catastrophic cascade of collisions' involving 300,000 pieces of rubbish must be averted, warn scientists
Oxford is the least affordable city in the UK, where houses cost 11 times local salaries
Swarm of killer bees sting woman 1,000 times
Malaysia Airlines Flight MH370: Oil slicks in South China Sea ‘not from missing jet’, officials say
Steve Irwin’s final words: Cameraman present at death opens up about deadly stingray attack for the first time
Oscar Pistorius trial: Athlete repeatedly throws up as court hears 'graphic details' of Reeva Steenkamp's autopsy
Britain's top vet sparks controversy with call for ban on slashing animals' throats in 'ritual' slaughters for halal and kosher meat products
Poor 'live like animals' says Boris's privately educated sister after going on 'poverty safari'
Exclusive: Impact of immigrants on British workers ‘negligible’
Vince Cable: Teachers 'know absolutely nothing' about the world of work
Ukraine crisis: Russia pledges to 'retaliate against sanctions' as Ukrainian president says Crimea vote will not be recognised
The quiet diplomat: Catherine Ashton - recognised and admired in all the world’s troubled countries, yet ridiculed at home
- 1 Oxford is the least affordable city in the UK, where houses cost 11 times local salaries
- 2 Australian man Rod Sommerville reacts to bite from deadly snake by reaching for cold beer
- 3 North Korea elections: Kim Jong-un wins 100% of the vote
- 4 David Cameron resorts to paying for Facebook fans because not enough people like him
- 5 Steve Irwin’s final words: Cameraman present at death opens up about deadly stingray attack for the first time
iJobs Money & Business
£32000 - £36000 per annum + generous benefits: Pro-Recruitment Group: * TAX * ...
£55000 - £70000 per annum + benefits: Pro-Recruitment Group: In-House Corporat...
£80000 - £100000 per annum + benefits: Pro-Recruitment Group: In-House Opportu...
£30000 - £35000 per annum + generous benefits: Pro-Recruitment Group: Mixed Ta...